Page 30 - ESHRE2019

Textbook of Clinical Trials, 2nd Edition (Wiley) David Machin (Editor), Simon Day (Co-Editor), Sylvan Green (Co-Editor) 2006 Multiplicity in randomised trials II: subgroup and interim analyses. Schulz KF, Grimes DA. Lancet. 2005 May 7-13;365(9471):1657-61.
An overview of clinical research: the lay of the land. Grimes DA, Schulz KF Lancet. 2002 Jan 5;359(9300):57-61.
Multiplicity in randomised trials I: endpoints and treatments. Schulz KF, Grimes DA. Lancet. 2005 Apr 30-May 6;365(9470):1591-5.
Sample size calculations in randomised trials: mandatory and mystical. Schulz KF, Grimes DA. Lancet. 2005 Apr 9-15;365(9467): 1348-53.
Unequal group sizes in randomised trials: guarding against guessing. Schulz KF, Grimes DA. Lancet. 2002 16;359(9310):966-70.
Sample size slippages in randomised trials: exclusions and the lost and wayward. Schulz KF, Grimes DA. Lancet. 2002 2;359(9308): 781-5.
Blinding in randomised trials: hiding who got what. Schulz KF, Grimes DA. Lancet. 2002 Feb 23;359(9307):696-700.
Allocation concealment in randomised trials: defending against deciphering.Schulz KF, Grimes DA. Lancet. 200216;359(9306):614-8 Generation of allocation sequences in randomised trials: chance, not choice. Schulz KF, Grimes DA.Lancet. 20029;359(9305):515-9
28
25